Longeveron shares surge 13.95% premarket after U.S. patent grant for stem cell therapy treating female sexual dysfunction.

Longeveron surged 13.95% in premarket trading following the announcement that the U.S. Patent and Trademark Office granted a patent (No. 12,496,316) for its mesenchymal stem cell therapy targeting female sexual dysfunction. The patent, valid through 2038, covers methods of administering allogeneic MSCs to improve sexual quality of life in female patients, addressing a condition affecting up to 46% of women with limited treatment options. The company highlighted plans to pursue licensing or partnering agreements for commercialization, expanding its aging-focused IP portfolio. The grant reinforces Longeveron’s regenerative medicine pipeline, which includes FDA-designated therapies for Alzheimer’s and pediatric heart conditions, and underscores potential market opportunities for its proprietary stem cell technology.